Insulin Resistance By Age 30 Quite Telling Of Future Heart Health
AIThis post was created with the assistance of artificial intelligence (AI).

TL;DR

A CARDIA cohort analysis found that insulin resistance in young adulthood was associated with a higher risk of atherosclerotic cardiovascular disease (ASCVD) later in life. Midlife metabolic syndrome statistically mediated 63.4% of the association, but the observational study cannot show that insulin resistance causes future events or that treating it prevents them.

A long-running analysis of 3,622 CARDIA participants found that insulin resistance measured in young adulthood was associated with a 50% higher relative risk of later ASCVD events among those followed into middle age. The observational findings, reported by researchers led by Chuyue Wu of UCLA, also indicate that metabolic syndrome in midlife accounted statistically for much of that association; they do not establish that insulin resistance directly causes heart disease.

Before you orderOffer from Amazon

Get workout gear delivered free with Prime

  • Fast, free delivery on millions of items
  • Prime Video, Amazon Music and more included
  • Member-only deals all year
Start your free Prime trial Free trial for eligible customers · Cancel anytime
As an affiliate, we earn on qualifying purchases.

Participants entered the study in 1985–86 at a mean age of 25 years; 45% were men and 47% were Black. The analysis focused on those who remained free of ASCVD through year 20, when they were ages 38 to 50. About one in four had insulin resistance at baseline. Researchers then tracked ASCVD events through year 35, when participants were 53 to 65.

Over a median of 14 years after year 20, 3.9% of participants experienced an ASCVD event. Compared with participants without insulin resistance at baseline, those with it had a risk ratio of 1.50 (95% confidence interval 1.13–2.01). This is a relative-risk estimate, not a finding that half of participants developed disease or an estimate of any one person’s absolute risk.

The researchers defined insulin resistance using a fasting blood-test calculation, HOMA-IR, at or above the cohort’s 75th percentile: 2.67 or higher. Participants fasted for 12 hours. The study’s authors noted that this indirect measure may not match the hyperinsulinemic-euglycemic clamp, a reference method for measuring insulin resistance. They also found that midlife metabolic syndrome statistically mediated 63.4% of the association, with an indirect risk ratio of 1.29 (95% CI 1.13–1.48).

At a glance
reportWhen: Published November 20, 2026; participan…
The developmentA CARDIA cohort analysis reported an association between insulin resistance in young adulthood and higher ASCVD risk in middle age.

Why Early Risk Signals Matter

The findings put attention on a period when many people may not yet have a cluster of conventional cardiovascular risk factors. The researchers suggest that insulin resistance in young adulthood could signal a trajectory that later includes changes in waist size, blood pressure, glucose and blood lipids. That possibility matters because identifying concerning patterns before several risk factors accumulate could help clinicians and patients discuss monitoring and prevention earlier.

However, the analysis does not show that screening young adults for insulin resistance, or changing insulin resistance itself, will prevent cardiovascular events. The authors say it remains to be determined whether HOMA-IR improves risk prediction beyond routinely measured clinical factors and whether delaying metabolic syndrome reduces later ASCVD risk. The results are a reason for further study, not proof of a new treatment or screening standard.

Products Worth Considering

As an affiliate, we earn on qualifying purchases.

How CARDIA Tracked Risk

CARDIA is a multicenter, population-based prospective study that repeatedly assessed participants over decades. For this analysis, researchers excluded people who had developed ASCVD before year 20, then examined whether insulin resistance recorded at enrollment was associated with events during later follow-up. That design establishes the order in which measurements and outcomes occurred, but it remains observational and cannot rule out other explanations for the association.

Midlife metabolic syndrome was defined as meeting at least three of five criteria: elevated waist circumference, high triglycerides, low HDL cholesterol, elevated blood pressure or use of blood-pressure medication, and elevated fasting glucose or use of glucose-lowering medication. The report describes insulin resistance as not routinely measured in clinical practice, which limits direct translation of its study threshold into everyday screening.

“Insulin resistance in young adulthood may signal an adverse CKM trajectory before conventional cardiometabolic risk factors become fully established.”

— Chuyue Wu and colleagues, writing in JACC: Advances

Limits of the Risk Estimate

The study was observational, so residual confounding may explain some of the relationship; the analysis cannot establish cause and effect. The authors also did not account for changes in metabolic syndrome or its individual components before or after the year-20 assessment. The number of participants with events was limited: 3.9% had ASCVD events during the specified follow-up, so the relative-risk result should not be treated as an individual prediction.

It is also not clear whether the HOMA-IR threshold used in this cohort would be useful for routine clinical risk assessment. Fasting insulin is not commonly measured, and the authors say further research is needed on practical ways to identify insulin resistance when that measurement is unavailable. The study does not report that an intervention aimed at insulin resistance or metabolic syndrome reduced later ASCVD events.

Research Needed Before Practice Changes

The study authors called for research to test whether HOMA-IR adds useful information beyond standard clinical measures, develop practical identification methods, and determine whether preventing or delaying metabolic syndrome lowers subsequent ASCVD risk. Until those questions are answered, the report does not establish a new screening recommendation.

For now, the editorialists argue that clinicians should pay attention to patterns of changing cardiometabolic measures in young adults, including abdominal adiposity, blood pressure, triglycerides and glycemic measures. Whether such earlier monitoring leads to fewer cardiovascular events remains to be tested.

Key Questions

What did the CARDIA analysis find?

Insulin resistance measured in young adulthood was associated with a higher relative risk of ASCVD events later in middle age. The study was observational and does not prove that insulin resistance caused those events.

Does this mean young adults with insulin resistance will develop heart disease?

No. The reported risk ratio compares groups; it is not a prediction for an individual. In the analyzed group, 3.9% experienced ASCVD events during a median 14 years of follow-up after year 20.

How was insulin resistance measured?

Researchers used HOMA-IR, calculated from fasting measurements, and classified values of 2.67 or higher as insulin resistance for this analysis. The authors cautioned that this indirect measure may not correspond exactly to the clamp method used as a reference.

Does the report recommend routine HOMA-IR testing?

No new testing recommendation was established. The authors said further research is needed to find out whether HOMA-IR improves risk prediction beyond routinely measured clinical factors and how insulin resistance could be identified when fasting insulin is unavailable.

Source: medpagetoday.com

Wellness content on this site is informational and not a substitute for professional medical guidance.
You May Also Like

Medtronic Surges In Global Coverage

Search interest in Medtronic has spiked significantly, with 62 media mentions in the recent window, indicating rising global attention to the medical device company.

Cancer GoFundMe Shut Down; ‘Dialed Down’ Drug Price Plan; Binge Drinking And Cancer

GoFundMe closed a cancer-treatment fundraiser that raised more than $700,000, while a Medicare drug-price proposal was reportedly scaled back.

Shirley Ballas looks back: ‘I was crying about a breakup, so Mum smacked me round the face’

Shirley Ballas recalls her mother smacking her after crying over a breakup during a holiday, highlighting her disciplined upbringing and close bond.

The Shoe Rotation Habit That Helps More Than Just Foam Recovery

Just rotating your shoes can do more than recover foam—it also prevents injuries and extends your shoes’ lifespan, so keep reading to learn how.